-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

Benzinga·09/09/2026 18:21:21
Listen to the news
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.